PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

Judith van Loon; Aniek J G Even; Hugo J W L Aerts; Michel Öllers; Frank Hoebers; Wouter van Elmpt; Ludwig Dubois; Anne-Marie C Dingemans; Roy I Lalisang; Pascal Kempers; Boudewijn Brans; Véronique Winnepenninckx; Ernst-Jan Speel; Eric Thunnissen; Kim M Smits; Ronald Boellaard; Danielle J Vugts; Dirk De Ruysscher; Philippe Lambin

doi:https://doi.org/10.1016/j.radonc.2016.11.020

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

Judith van Loon, Aniek J G Even, Hugo J W L Aerts, Michel Öllers, Frank Hoebers, Wouter van Elmpt, Ludwig Dubois, Anne-Marie C Dingemans, Roy I Lalisang, Pascal Kempers, Boudewijn Brans, Véronique Winnepenninckx, Ernst-Jan Speel, Eric Thunnissen, Kim M Smits, Ronald Boellaard, Danielle J Vugts, Dirk De Ruysscher, Philippe Lambin

Radiology and Nuclear Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

46 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)Zr-cetuximab and to assess tumour uptake.

METHODS: Two dose schedules were used; two consecutive doses of 60MBq (89)Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.

RESULTS: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of (89)Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR)>1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals>5days after injection.

CONCLUSIONS: Both presented (89)Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.

Original language	English
Journal	Radiotherapy and oncology
DOIs	https://doi.org/10.1016/j.radonc.2016.11.020
Publication status	Published - 21 Dec 2016

Access to Document

https://doi.org/10.1016/j.radonc.2016.11.020

Cite this

van Loon, J., Even, A. J. G., Aerts, H. J. W. L., Öllers, M., Hoebers, F., van Elmpt, W., Dubois, L., Dingemans, A.-M. C., Lalisang, R. I., Kempers, P., Brans, B., Winnepenninckx, V., Speel, E.-J., Thunnissen, E., Smits, K. M., Boellaard, R., Vugts, D. J., De Ruysscher, D., & Lambin, P. (2016). PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiotherapy and oncology. https://doi.org/10.1016/j.radonc.2016.11.020

@article{be1f38ccb79243199217980292b3f8a4,

title = "PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer",

abstract = "BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)Zr-cetuximab and to assess tumour uptake.METHODS: Two dose schedules were used; two consecutive doses of 60MBq (89)Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.RESULTS: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of (89)Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR)>1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals>5days after injection.CONCLUSIONS: Both presented (89)Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.",

author = "{van Loon}, Judith and Even, {Aniek J G} and Aerts, {Hugo J W L} and Michel {\"O}llers and Frank Hoebers and {van Elmpt}, Wouter and Ludwig Dubois and Dingemans, {Anne-Marie C} and Lalisang, {Roy I} and Pascal Kempers and Boudewijn Brans and V{\'e}ronique Winnepenninckx and Ernst-Jan Speel and Eric Thunnissen and Smits, {Kim M} and Ronald Boellaard and Vugts, {Danielle J} and {De Ruysscher}, Dirk and Philippe Lambin",

year = "2016",

month = dec,

day = "21",

doi = "https://doi.org/10.1016/j.radonc.2016.11.020",

language = "English",

journal = "Radiotherapy and oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

van Loon, J, Even, AJG, Aerts, HJWL, Öllers, M, Hoebers, F, van Elmpt, W, Dubois, L, Dingemans, A-MC, Lalisang, RI, Kempers, P, Brans, B, Winnepenninckx, V, Speel, E-J, Thunnissen, E, Smits, KM, Boellaard, R , Vugts, DJ, De Ruysscher, D & Lambin, P 2016, 'PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer', Radiotherapy and oncology. https://doi.org/10.1016/j.radonc.2016.11.020

TY - JOUR

T1 - PET imaging of zirconium-89 labelled cetuximab

T2 - A phase I trial in patients with head and neck and lung cancer

AU - van Loon, Judith

AU - Even, Aniek J G

AU - Aerts, Hugo J W L

AU - Öllers, Michel

AU - Hoebers, Frank

AU - van Elmpt, Wouter

AU - Dubois, Ludwig

AU - Dingemans, Anne-Marie C

AU - Lalisang, Roy I

AU - Kempers, Pascal

AU - Brans, Boudewijn

AU - Winnepenninckx, Véronique

AU - Speel, Ernst-Jan

AU - Thunnissen, Eric

AU - Smits, Kim M

AU - Boellaard, Ronald

AU - Vugts, Danielle J

AU - De Ruysscher, Dirk

AU - Lambin, Philippe

PY - 2016/12/21

Y1 - 2016/12/21

N2 - BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)Zr-cetuximab and to assess tumour uptake.METHODS: Two dose schedules were used; two consecutive doses of 60MBq (89)Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.RESULTS: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of (89)Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR)>1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals>5days after injection.CONCLUSIONS: Both presented (89)Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.

AB - BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)Zr-cetuximab and to assess tumour uptake.METHODS: Two dose schedules were used; two consecutive doses of 60MBq (89)Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.RESULTS: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of (89)Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR)>1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals>5days after injection.CONCLUSIONS: Both presented (89)Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.

U2 - https://doi.org/10.1016/j.radonc.2016.11.020

DO - https://doi.org/10.1016/j.radonc.2016.11.020

M3 - Article

C2 - 28012793

SN - 0167-8140

JO - Radiotherapy and oncology

JF - Radiotherapy and oncology

ER -